| (Values in U.S. Thousands) | Sep, 2024 | Jun, 2024 | Mar, 2024 | Dec, 2023 | Sep, 2023 |
| Sales | 490 | 800 | 570 | 300 | 180 |
| Sales Growth | -38.75% | +40.35% | +90.00% | +66.67% | +63.64% |
| Net Income | -8,460 | -8,560 | -8,390 | -9,160 | -9,860 |
| Net Income Growth | +1.17% | -2.03% | +8.41% | +7.10% | -9.92% |
Oncternal Therapeutics Inc
(ONCT)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
by (Cboe BZX)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
[[ item.lastPriceExt ]]
[[ item.priceChangeExt ]]
([[ item.percentChangeExt ]])
[[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Oncternal Therapeutics Inc. is a clinical-stage oncology company. It is engaged in developing treatments for cancers with critical unmet medical need. The company's pipeline includes cirmtuzumab, TK-216 and CAR-T therapy that targets ROR1 which are in clinical stage. Oncternal Therapeutics Inc., formerly known as GTx Inc., is based in San Diego, California.
Fiscal Year End Date: 12/31